Status:

RECRUITING

UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study

Lead Sponsor:

University of North Carolina, Chapel Hill

Collaborating Sponsors:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

United States President's Emergency Plan for AIDS Relief

Conditions:

Pre-exposure Prophylaxis

HIV Prevention

Eligibility:

FEMALE

15-55 years

Phase:

PHASE4

Brief Summary

The primary purpose of this study is to assess the safety of long-acting injectable cabotegravir (CAB-LA) and oral pre-expose prophylaxis (PrEP) (FTC/TDF or 3TC/TDF) for the prevention of HIV during p...

Detailed Description

For the prospective safety cohort, the study will enroll and follow up eligible women attending antenatal clinic and planning to deliver at Bwaila District Hospital in Lilongwe, Malawi. The primary ob...

Eligibility Criteria

Inclusion

  • Maternal participants:
  • Confirmed pregnancy by urine pregnancy test or ultrasound.
  • Aged 15 years or older
  • PrEP-eligible by Malawi local guidelines
  • Confirmed HIV-negative based on the local HIV testing algorithm
  • Hepatitis B surface antigen (HBsAg) negative
  • Weight \>35 kg
  • Provided informed consent and expressed willingness to participate in study activities with their infants.
  • Infant participants: Infant participants will enter the study with their mother as unborn infants. There are no specific eligibility criteria for infant participation otherwise.

Exclusion

  • Maternal participants will not be eligible to enter the prospective cohort study if any of the following conditions are identified during the screening process:
  • Known to be living with HIV
  • Known allergies to CAB-LA, TDF/3TC or FTC/TDF
  • Other current significant disease process (active or chronic), substance use, or social circumstances that, in the judgment of the site investigator would make participation in the study unsafe.
  • Intention to leave the study site's catchment area of Bwaila before scheduled study exit.

Key Trial Info

Start Date :

April 17 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2027

Estimated Enrollment :

621 Patients enrolled

Trial Details

Trial ID

NCT06158126

Start Date

April 17 2024

End Date

December 1 2027

Last Update

March 14 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Bwaila Distict Hospital

Lilongwe, Malawi